Comparison of Hodgkin's Lymphoma in Children and Adolescents. A Twenty Year Experience with MH'96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols.
Hodgkin’s lymphoma
adolescent
chemotherapy
children
clinical characteristics
histology
pediatric
prognosis
radiotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Jun 2020
18 Jun 2020
Historique:
received:
29
04
2020
revised:
01
06
2020
accepted:
16
06
2020
entrez:
24
6
2020
pubmed:
24
6
2020
medline:
24
6
2020
Statut:
epublish
Résumé
Adolescents and young adults (AYAs) represent a distinct group of patients. The objectives of this study were: To compare adolescent prognosis to that of younger children; to compare the results achieved with the two consecutive protocols in both age groups; to analyze clinical characteristics of children and adolescents. Between 1996 and 2017, 1759 patients aged <18 years were evaluable for the study. Five hundred and sixty patients were treated with the MH'96 protocol and 1199 with the LH2004 protocol. Four hundred and eighty-two were adolescents aged ≥15 years. Patients in both age groups showed very favorable prognoses. In particular, OS improved with the LH2004 protocol, especially in the adolescent group and in the low risk group, where radiation therapy was spared. Adolescent characteristics differed significantly from the children's according to sex, histology, and the presence of symptoms. Remarkable is the decrease both in mixed cellularity in the children and in low stages in both age groups in the LH2004 protocol with respect to MH'96 protocol. Based on our experience, adopting pediatric protocols for AYA does not compromise patient outcomes.
Identifiants
pubmed: 32570974
pii: cancers12061620
doi: 10.3390/cancers12061620
pmc: PMC7352443
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Leuk Lymphoma. 2004 Aug;45(8):1579-85
pubmed: 15370209
J Adolesc Young Adult Oncol. 2019 Dec;8(6):684-696
pubmed: 31411521
J Adolesc Young Adult Oncol. 2020 Apr;9(2):196-201
pubmed: 31747324
Cancer. 2006 Oct 1;107(7 Suppl):1645-55
pubmed: 16906507
J Adolesc Young Adult Oncol. 2019 Aug;8(4):402-409
pubmed: 30912693
Clin Med Insights Oncol. 2018 Jan 31;12:1179554918754885
pubmed: 29434481
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Cancer. 2016 Apr 1;122(7):1009-16
pubmed: 26848927
Front Oncol. 2014 Nov 28;4:317
pubmed: 25506581
Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):e267-e273
pubmed: 29739722
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):377-80
pubmed: 17372233
Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225
pubmed: 23585445
J Adolesc Young Adult Oncol. 2020 May 15;:
pubmed: 32412825
Anticancer Res. 2007 Mar-Apr;27(2):1191-7
pubmed: 17465262
Eur J Cancer. 2015 Nov;51(17):2643-54
pubmed: 26321503
JAMA Pediatr. 2016 May 1;170(5):495-501
pubmed: 26999630
Cancer. 2018 Jan 1;124(1):136-144
pubmed: 28902390
Leuk Lymphoma. 2018 Nov;59(11):2612-2621
pubmed: 29448858
Oncotarget. 2017 Sep 6;8(45):80073-80082
pubmed: 29108389
Br J Haematol. 2019 Jan;184(1):72-81
pubmed: 30460695
J Clin Oncol. 2006 Jun 1;24(16):2520-6
pubmed: 16735704
Br J Haematol. 2009 Jan;144(1):24-40
pubmed: 19087093
J Clin Oncol. 1997 Aug;15(8):2769-79
pubmed: 9256118
Cancer Epidemiol. 2016 Jun;42:72-81
pubmed: 27054577
Cancer Med. 2020 May 22;:
pubmed: 32441450
Pediatr Blood Cancer. 2017 Dec;64(12):
pubmed: 28612375
Curr Opin Pediatr. 2003 Feb;15(1):10-6
pubmed: 12544266
J Clin Oncol. 2010 Aug 10;28(23):3680-6
pubmed: 20625128
Cancer Radiother. 2020 Jun;24(3):206-214
pubmed: 32171674
Cancer Treat Rev. 2007 Nov;33(7):631-45
pubmed: 17329031
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1474-88
pubmed: 26215294
J Clin Oncol. 2003 Sep 15;21(18):3431-9
pubmed: 12885835
Acta Haematol. 2014;132(3-4):274-8
pubmed: 25228552
Acta Oncol. 2018 Feb;57(2):276-282
pubmed: 28760045
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):97-106
pubmed: 30219963
Pediatr Blood Cancer. 2016 Jun;63(6):1116-9
pubmed: 26914476
J Clin Oncol. 2000 Apr;18(7):1500-7
pubmed: 10735898
CA Cancer J Clin. 2018 Mar;68(2):116-132
pubmed: 29194581
J Clin Oncol. 1999 Dec;17(12):3736-44
pubmed: 10577845
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):323-330
pubmed: 27913498
Cancer. 2019 May 1;125(9):1558-1567
pubmed: 30620388
Paediatr Child Health. 2008 Jan;13(1):19-24
pubmed: 19119348
Clin Transl Oncol. 2018 Oct;20(10):1289-1301
pubmed: 29623582
J Clin Oncol. 2001 Apr 1;19(7):2026-32
pubmed: 11310450
Br J Cancer. 2008 Sep 2;99(5):830-5
pubmed: 18728673
Cancer. 2019 Jun 15;125(12):2107-2114
pubmed: 30892701
J Clin Oncol. 2009 Dec 20;27(36):6079-85
pubmed: 19901121
JAMA. 2011 Jun 8;305(22):2311-9
pubmed: 21642683
Br J Haematol. 2020 Jun;189(6):1093-1106
pubmed: 32030738
Pediatr Blood Cancer. 2019 Jun;66(6):e27620
pubmed: 30815990
Eur J Cancer. 2009 Feb;45(3):328-34
pubmed: 19135358
Int J Oncol. 2008 Jul;33(1):145-51
pubmed: 18575760
J Pediatr Hematol Oncol. 2011 Mar;33(2):e60-3
pubmed: 21285900
Eur J Cancer. 2006 Sep;42(13):2037-49
pubmed: 16919769
Cancer. 2019 Jul 1;125(13):2283-2290
pubmed: 30901085
Neoplasma. 2019 Jul 12;66(6):978-987
pubmed: 31305124
J Clin Oncol. 1985 Nov;3(11):1495-502
pubmed: 3903063
Br J Haematol. 2018 Nov;183(3):385-399
pubmed: 30095154
Cancer Treat Rev. 2019 Jul;77:44-56
pubmed: 31260900
Am J Hematol. 2018 Feb;93(2):238-245
pubmed: 29114948
Oncogene. 2003 Aug 11;22(33):5108-21
pubmed: 12910248
Cancer Med. 2019 Aug;8(10):4918-4927
pubmed: 31264807
J Clin Oncol. 2010 Mar 1;28(7):1232-9
pubmed: 20124178